Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

Clinical Journal of the American Society of Nephrology (CJASN)
22/02/2021 4 min
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

Listen "Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria "

Descargar episodio Ver en sitio original

Episode Synopsis

Drs. Meg Jardine and Carinna Hockham discuss the findings from their study "Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria," on behalf of their colleagues.

More episodes of the podcast Clinical Journal of the American Society of Nephrology (CJASN)

Comparative Effectiveness of Lubiprostone and Stool Softeners in CKD 28/10/2025
SGLT2 Inhibition and Hospitalizations in Patients with Chronic Kidney Disease 30/09/2025
Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative Glomerulonephritis 27/08/2025
Perceptions of Future Earnings Among Nephrology Fellows 25/07/2025
SGLT2 Inhibitors and Risk of Urinary Tract Infections with Abnormal Genitourinary Pathology 27/06/2025
Transition Practices in Pediatric and Adult Nephrology 23/04/2025
Creatinine and Cystatin-Based Equations in People with Cancer 25/03/2025
GLP1 Receptor Agonists and Kidney Outcomes 14/02/2025
Anticoagulation and Fracture Risk in CKD Patients with Atrial Fibrillation 23/01/2025
Comparing USRDS vs. National Death Index on Sudden Cardiac Death in Dialysis Patients 23/12/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA